April 01, 2017 + Jessica Di Palo
5 Min read
Basel, April 2017 – MTIP MedTech Innovation Partners AG has closed its first fund significantly above expectation at CHF 60 million.
After its launch a year ago, MTIP’s first fund closed at a total of just under CHF 60 million. Due to strong investor demand this is considerably higher than the CHF 40 million targeted at the outset. “A first fund of this magnitude is exceptional in the industry and a great success for our investors and us,” explains Dr. Christoph Kausch, CEO of MTIP. The capital comes from institutional investors such as pension funds and family offices, hospitals, foundations and qualified private individuals. MTIP will use this fund to invest in a portfolio of around 10 startups in the medical technology sector. The aim is to support these businesses and to facilitate their further development into successful companies. Having invested in two startups (Coramaze and Reactive Robotics) already, additional investments are expected later this year as MTIP’s project pipeline is looking promising with additional attractive opportunities. “MTIP’s involvement in the innovation landscape, from university research to practical use in hospitals and an understanding of the relevant MedTech players’ portfolio strategies are important success factors in our business model”, emphasises board president Dr. Felix Grisard. In the selection process of companies MTIP places a clear focus on health economic benefits and patient-relevant innovations. MTIP builds sustainable investments that facilitate improved health care at home and abroad and combine economic success with added value for the community.
SFDR Art. 8 or Art. 9? What’s the difference?
SFDR: getting the terminology right
MTIP participates in Oviva’s new $80m Series C funding
Oviva raises $80 million financing round
MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence
MTIP's new investment in Intelligencia
Private Equity 101: Part one – Glossary
Are you new to the healthtech space?
Leading brands revolutionize care journeys with Lumeon
How Lumeon orchestrates care journey
Trialbee – our hero in patient matching and recruiting for clinical trials
Trialbee - patient matching and recruiting
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
How to pitch to a healthtech Investor
MTIP invests in Koa Health to make mental health treatment more accessible
New investment in Koa Health
MTIP scored fantastic grades in the UNPRI assessment report of 2020
UNPRI Report grades 2020
4 Health VCs Share Their Business Priorities and What is Next
MTIP invests in Trialbee
New investment in Trialbee
TytoCare closes $50 million round as the demand for telehealth accelerates
TytoCare closes new round
The digital healthtech sector is expanding – and so are we!
Two new empolyees start in April
MTIP has sucessfully exited Blueprint Genetics
Blueprint exit January 2020
New MTIP investment in Oviva
New investment in Oviva
Whitepaper: A positive prognosis for the future of healthtech
Our first Whitepaper
Elite Summit 2019 – Interview with our Managing Partner Christoph Kausch
Elite Summit 2019
MTIP Healthcare Clinic 2019
Healthcare clinic 2019
New MTIP investment in Cynerio
New investment in Cynerio
MTIP invests in Lumeon Ltd.
New investment in Lumeon
Magenverkleinerung mit der Handnähmaschine
Nitinotes news paper article
New MTIP investment in Quanta Dialysis Technologies
New investment in Quanta